

DAFTAR PUSTAKA

- Adham, M., Kurniawan, A. N., Muhtadi, A. I., Roezin, A., Hermani, B., Gondhowiardjo, S., Tan I. B., Middeldorp, J. M., 2012. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. *Chinese Journal of Cancer*, 31(4), 185–196. <https://doi.org/10.5732/cjc.011.10328>
- Adham, M., Stoker, S. D., Wildeman, M. A., dkk., 2014. Current status of cancer care for young patients with nasopharyngeal carcinoma in Jakarta, Indonesia. *PloS one*, 9(7), e102353. doi:10.1371/journal.pone.0102353
- Adhikary, D., Behrends, U., Moosmann, A., Witter, K., Bornkamm, G. W., Mautner, J., 2006. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. *The Journal of experimental medicine*, 203(4), 995–1006. doi:10.1084/jem.20051287
- Al-Sarraf, M., LeBlanc, M., Giri, P. G., dkk., 1998. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. *Journal of Clinical Oncology*, 16(4), 1310–1317. doi:10.1200/jco.1998.16.4.1310
- Amyes, E., Hatton, C., Montamat-Sicotte, D., Gudgeon, N., Rickinson, A. B., McMichael, A. J., Callan, M. F., 2003. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. *The Journal of experimental medicine*, 198(6), 903–911. doi:10.1084/jem.20022058
- Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., Winchester, D. P., 2017. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. *CA: A Cancer Journal for Clinicians*, 67(2), 93–99. <https://doi.org/10.3322/caac.21388>
- Armstrong, R. W., Imrey, P. B., Lye, M. S., Armstrong, M. J., Yu, M. C., Sani, S., 2000. Nasopharyngeal carcinoma in Malaysian Chinese: occupational exposures to particles, formaldehyde and heat. *International Journal of Epidemiology*, 29(6), 991–998. doi:10.1093/ije/29.6.991
- Bei, J.X., Jia, W. H., Zeng, Y. X., 2012. Familial and large-scale case–control studies identify genes associated with nasopharyngeal carcinoma. *Seminars in Cancer Biology*, 22(2), 96–106. doi:10.1016/j.semcancer.2012.01.012

- Beigzadeh, Z., Pourhassan, B., kalantary, S., Golbabaei, F., 2018. Occupational exposure to wood dust and risk of nasopharyngeal cancer: A systematic review and meta-analysis. *Environmental Research*. doi:10.1016/j.envres.2018.12.022
- Bercin, S., Yalciner, G., Muderris, T., Gul, F., Deger, H. M., Kiris, M., 2017. Pathologic Evaluation of Routine Nasopharynx Punch Biopsy in the Adult Population: Is It Really Necessary?. *Clinical and experimental otorhinolaryngology*, 10(3), 283–287. doi:10.21053/ceo.2015.01256
- Bouvard V., Baan R., Straif K., dkk., 2009. A review of human carcinogens – part B: biological agents. *Lancet Oncol*, 10(4), 321–2. doi: 10.1016/S1470-2045(09)70096-8
- Boyle, D. S., Lehman, D. A., Lillis, L., dkk., 2013. Rapid detection of HIV-1 proviral DNA for early infant diagnosis using recombinase polymerase amplification. *mBio*, 4(2), e00135-13. doi:10.1128/mBio.00135-13
- Butler, S.A., Khanlian, S.A., Cole, L.A., 2001. Detection of early pregnancy forms of human chorionic gonadotropin by home pregnancy test devices. *Clin Chem*, 47(12), 2131-6
- Catalina, M. D., Sullivan., J. L., Bak, K. R., Luzuriaga, K., 2001. Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection. *J Immunol*, 167, 4450-7
- CCSNPC., 2013. Report on revision of the Chinese 1992 staging system for nasopharyngeal carcinoma. *J Radiat Oncol*, 2(3), 233–240.
- Chang, E. T., & Adami, H., 2006. The Enigmatic Epidemiology of Nasopharyngeal Carcinoma. *Cancer Epidemiology Biomarkers & Prevention*, 15(10), 1765–1777. doi:10.1158/1055-9965.epi-06-0353
- Charan, J., & Biswas, T., 2013. How to calculate sample size for different study designs in medical research?. *Indian journal of psychological medicine*, 35(2), 121–126. doi:10.4103/0253-7176.116232
- Cheesman, K., & Burdett, E., 2011. Anatomy of the nose and pharynx. *Anaesthesia and Intensive Care Medicine*, 12(7), 283–286. <https://doi.org/10.1016/j.mpaic.2011.04.013>
- Chen, J.Y., Chen, C.J., Liu, M.Y., dkk., 1987. Antibodies to Epstein-Barr virus-specific DNase in patients with nasopharyngeal carcinoma and control

groups. *Journal of Medical Virology*, 23(1), 11–21.
doi:10.1002/jmv.1890230103

Chen, Q.-Y., Wen, Y. F., Guo, L., dkk., 2011. Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: Phase III Randomized Trial. *JNCI: Journal of the National Cancer Institute*, 103(23), 1761–1770. doi:10.1093/jnci/djr432

Chen, W. S., Li, J. J., Hong, L., Xing, Z. B., Wang, F., Li, C. Q., 2016. Comparison of MRI, CT and 18F-FDG PET/CT in the diagnosis of local and metastatic of nasopharyngeal carcinomas: an updated meta analysis of clinical studies. *American journal of translational research*, 8(11), 4532–4547.

Cheng, Y. C., Chen, J. Y., Glaser, R., Henle, W., 1980. Frequency and levels of antibodies to Epstein-Barr virus-specific DNase are elevated in patients with nasopharyngeal carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, 77(10), 6162–6165. doi:10.1073/pnas.77.10.6162

Cho E. Y., Hildesheim A., Chen C. J., dkk., 2003. Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1. *Cancer Epidemiol Biomarkers Prev*, 12, 1100–1104.

Chua, M. L. K., Wee, J. T. S., Hui, E. P., & Chan, A. T. C., 2016. Nasopharyngeal carcinoma. *The Lancet*, 387(10022), 1012–1024. doi:10.1016/s0140-6736(15)00055-0

Craven, J. (2005). Anatomy of the naso- and oropharynx. *Anaesthesia & Intensive Care Medicine*, 6(7), 217–218. <https://doi.org/10.1383/anes.2005.6.7.217>

Dardari, R., Khyatti, M., Benider, A., dkk., 2000. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma. *International Journal of Cancer*, 86(1), 71–75. doi:10.1002/(sici)1097-0215(20000401)86:1<71::aid-ijc11>3.0.co;2-1

Deng, H., Zeng, Z., Lei, Z., dkk., 1995. Serological survey of nasopharyngeal carcinoma in 21 cities of south China. *Chin Med J (Engl)*, 108, 300-3

Draborg, A. H., Duus, K., Houen, G., 2013. Epstein-Barr virus in systemic autoimmune diseases. *Clinical & developmental immunology*, 2013, 535738. doi:10.1155/2013/535738

- Dukers, D. F., Meij, P., Vervoort, M. B. H. J., Vos, W., Scheper, R. J., Meijer, C. J. L. M., dkk., 2000. Direct Immunosuppressive Effects of EBV-Encoded Latent Membrane Protein 1. *The Journal of Immunology*, 165(2), 663–670. doi:10.4049/jimmunol.165.2.663
- Epstein, M.A., Henle, G., Achong, B.G., Barr, Y.M., 1965 Morphological and Biological Studies on a Virus in Cultured Lymphoblast from Burkitt's lymphoma. *J Exp Med*, 121, 761-70
- Fachiroh, J., Paramita, D. K., Hariwiyanto, B., Harijadi, A., Dahlia, H. L., Indrasari, S. R., Kusumo, H., Zeng, Y. S., Schouten, T., Mubarika, S., Middeldorp, J. M., 2005. Single-Assay Combination of Epstein-Barr Virus (EBV) EBNA1- and Viral Capsid Antigen-p18-Derived Synthetic Peptides for Measuring Anti-EBV Immunoglobulin G (IgG) and IgA Antibody Levels in Sera from Nasopharyngeal Carcinoma Patients: Options for Field Screening. *JOURNAL OF CLINICAL MICROBIOLOGY*, Apr. 2006, p. 1459-1467. <https://doi.org/10.1128/JCM.44.4.1459-1467.2006>
- Fachiroh, J., Prasetyanti, P. R., Paramita, D. K., Prasetyawati, A. T., Anggrahini, D. W., Haryana, S. M., & Middeldorp, J. M., 2008. *Dried-Blood Sampling for Epstein-Barr Virus Immunoglobulin G (IgG) and IgA Serology in Nasopharyngeal Carcinoma Screening. Journal of Clinical Microbiology*, 46(4), 1374–1380. doi:10.1128/jcm.01368-07
- Feederle, R., Neuhierl, B., Bannert, H., Geletneky, K., Shannon-Lowe, C., Delecluse, H. J., 2007. Epstein-Barr virus B95.8 produced in 293 cells shows marked tropism for differentiated primary epithelial cells and reveals interindividual variation in susceptibility to viral infection. *International Journal of Cancer*, 121(3), 588–594. doi:10.1002/ijc.22727
- Gartner, B. C., J. M., Fischinger, K., Roemer, M., Mak, B., Fleurent, N., Mueller-Lantzsch., 2001. Evaluation of a recombinant line blot for diagnosis of Epstein-Barr virus compared with ELISA using immunofluorescence as reference method. *J. Virol. Methods* 93:89-96.
- Glastonbury, C. M., Salzman, K. L., 2013. Pitfalls in the Staging of Cancer of Nasopharyngeal Carcinoma. *Neuroimaging Clinics of North America*, 23(1), 9–25. doi:10.1016/j.nic.2012.08.006
- Goh, J., Lim, K., 2009. Imaging of nasopharyngeal carcinoma. *Ann Acad Med Singapore*, 38, 809–816
- Goldsmith, D. B., West, T. M., Morton, R., 2002. HLA associations with nasopharyngeal carcinoma in Southern Chinese: a meta-analysis. *Clinical*

Otolaryngology and Allied Sciences, 27(1), 61–67. doi:10.1046/j.0307-7772.2001.00529.x

Guo X, Johnson RC, Deng H, et al. Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of southern China. *Int J Cancer* 2009; 124: 2942–47.

Henle, G., Henle, W., 1976. Epstein-barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. *International Journal of Cancer*, 17(1), 1–7. doi:10.1002/ijc.2910170102

Hildesheim, A., Anderson, L. M., Chen, C. J., dkk., 1997. CYP2E1 Genetic Polymorphisms and Risk of Nasopharyngeal Carcinoma in Taiwan. *JNCI: Journal of the National Cancer Institute*, 89(16), 1207–1212. doi:10.1093/jnci/89.16.1207

Hildesheim, A., Wang, C. P., 2012. Genetic predisposition factors and nasopharyngeal carcinoma risk: A review of epidemiological association studies, 2000–2011. *Seminars in Cancer Biology*, 22(2), 107–116. doi:10.1016/j.semcancer.2012.01.007

Hislop, A. D., Taylor, G. S., Sauce, D., Rickinson, A. B., 2007. Cellular Responses to Viral Infection in Humans: Lessons from Epstein-Barr Virus. *Annual Review of Immunology*, 25(1), 587–617. doi:10.1146/annurev.immunol.25.022106.141553

Ho, H. C., Ng, M. H., Kwan, H. C., Chau, J. C., 1976. Epstein-Barr-virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma. *British Journal of Cancer*, 34(6), 655–660. doi:10.1038/bjc.1976.228

Hoe J.W.M., 1989. Computed tomography of nasopharyngeal carcinoma. A review of CT appearances in 56 patients. *Eur J Radiol*, 9, 83–90

Bray F., Colombet M., Mery L., dkk., 2017. Cancer Incidence in China (2008-2012). *Cancer Incidence in Five Continents, XI*. Lyon: International Agency for Research on Cancer

Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D., 2011. Global cancer statistics. *CA: A Cancer Journal for Clinicians*, 61(2), 69–90. doi:10.3322/caac.20107

Ji, X., Zhang, W., Xie, C., Wang, B., Zhang, G., Zhou, F., 2010. Nasopharyngeal carcinoma risk by histologic type in central China: Impact of smoking,

alcohol and family history. *International Journal of Cancer*, 129(3), 724–732.
doi:10.1002/ijc.25696

Joab, I., Triki, B., de Saint Martin, J., Perricaudet, M., Nicolas, J. C., 1991. Detection of Anti-Epstein-Barr Virus trans-Activator (ZEBRA) Antibodies in Sera from Patients with Human Immunodeficiency Virus. *Journal of Infectious Diseases*, 163(1), 53–56. doi:10.1093/infdis/163.1.53

Kamran, S. C., Riaz, N., Lee, N., 2015. Nasopharyngeal Carcinoma. *Surgical Oncology Clinics of North America*, 24(3), 547–561. doi:10.1016/j.soc.2015.03.008

Kang, M., Zhou, P., Wei, T., Zhao, T., Long, J., Li, G., Wang, R., 2017. A new T staging system for nasopharyngeal carcinoma based on intensity-modulated radiation therapy: results from a prospective multicentric clinical study. *American journal of cancer research*, 7(2), 346–356.

Karray, H., Ayadi, W., Fki, L., Hammami, A., Daoud, J., Drira, M. M., dkk., 2005. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. *Journal of Medical Virology*, 75(4), 593–602. doi:10.1002/jmv.20310

Khabir, A., Karray, H., Rodriguez, S., Rosé, M., Daoud, J., Frikha, M., Busson, P., 2005. *Virology Journal*, 2(1), 39. doi:10.1186/1743-422x-2-39

Khabir, A., Karray, H., Rodriguez, S., Rosé, M., Daoud, J., Frikha, M., dkk., 2005. EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. *Virology journal*, 2, 39. doi:10.1186/1743-422X-2-39

Khanna, R., Burrows, S. R., Moss, D. J., 1995. Immune regulation in Epstein-Barr virus-associated diseases. *Microbiological reviews*, 59(3), 387–405.

King, A. D., & Bhatia, K. S., 2010. Magnetic resonance imaging staging of nasopharyngeal carcinoma in the head and neck. *World journal of radiology*, 2(5), 159–165. doi:10.4329/wjr.v2.i5.159

King, A. D., Vlantis, A. C., Bhatia, K. S. S., Zee, B. C. Y., Woo, J. K. S., Tse, G. M. K., dkk., 2011. Primary Nasopharyngeal Carcinoma: Diagnostic Accuracy of MR Imaging versus that of Endoscopy and Endoscopic Biopsy. *Radiology*, 258(2), 531–537. doi:10.1148/radiol.10101241

- King, A. D., Vlantis, A. C., Yuen, T. W. C., Law, B. K. H., Bhatia, K. S., Zee, B. C. Y., Ahuja, A. T., 2015. Detection of Nasopharyngeal Carcinoma by MR Imaging: Diagnostic Accuracy of MRI Compared with Endoscopy and Endoscopic Biopsy Based on Long-Term Follow-Up. *American Journal of Neuroradiology*, 36(12), 2380–2385. doi:10.3174/ajnr.a4456
- King, A. D., Wong, L. Y. S., Law, B. K. H., dkk., 2017. MR Imaging Criteria for the Detection of Nasopharyngeal Carcinoma: Discrimination of Early-Stage Primary Tumors from Benign Hyperplasia. *American Journal of Neuroradiology*, 39(3), 515–523. doi:10.3174/ajnr.a5493
- Kwiecien, R., Kopp-Schneider, A., Blettner, M., 2011. Review Article Concordance Analysis Part 16 of a Series on Evaluation of Scientific Publication. *Dtsch Arztebl Int* 2011; 108(30): 515-21. <https://doi.org/10.3238/arztebl.2011.0515>
- Kwong, D. L. W., Sham, J. S. T., Leung, L. H. T., dkk., 2006. Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. *International Journal of Radiation Oncology Biology Physics*, 64(2), 374–381. doi:10.1016/j.ijrobp.2005.07.968
- Laichalk, L. L., Hochberg, D., Babcock, G. J., Freeman, R. B., Thorley-Lawson, D. A., 2002. The Dispersal of Mucosal Memory B Cells. *Immunity*, 16(5), 745–754. doi:10.1016/s1074-7613(02)00318-7
- Lee, A. W. M., Ng, W. T., Chan, L. L. K., Hung, W. M., dkk., 2014. Evolution of treatment for nasopharyngeal cancer – Success and setback in the intensity-modulated radiotherapy era. *Radiotherapy and Oncology*, 110(3), 377–384. doi:10.1016/j.radonc.2014.02.003
- Lee, A. W. M., Ng, W. T., Chan, Y. H., Sze, H., Chan, C., Lam, T. H., 2012. The battle against nasopharyngeal cancer. *Radiotherapy and Oncology*, 104(3), 272–278. doi:10.1016/j.radonc.2012.08.001
- Leung, S., 2004. Improved Accuracy of Detection of Nasopharyngeal Carcinoma by Combined Application of Circulating Epstein-Barr Virus DNA and Anti-Epstein-Barr Viral Capsid Antigen IgA Antibody. *Clinical Chemistry*, 50(2), 339–345. doi:10.1373/clinchem.2003.022426
- Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A., Masucci, M. G., 1997. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. *Proceedings of the National Academy of Sciences of the United States of America*, 94(23), 12616–12621. doi:10.1073/pnas.94.23.12616

- Liao, X.B., Mao, Y.P., Liu, L.Z., dkk., 2008. How Does Magnetic Resonance Imaging Influence Staging According to AJCC Staging System for Nasopharyngeal Carcinoma Compared With Computed Tomography? *International Journal of Radiation Oncology Biology Physics*, 72(5), 1368–1377. doi:10.1016/j.ijrobp.2008.03.017
- Liu, Z., Ji, M.-F., Huang, Q., Fang, F., Liu, Q., Jia, W., Cao, S., 2012. Two Epstein-Barr Virus-Related Serologic Antibody Tests in Nasopharyngeal Carcinoma Screening: Results From the Initial Phase of a Cluster Randomized Controlled Trial in Southern China. *American Journal of Epidemiology*, 177(3), 242–250. doi:10.1093/aje/kws404
- Liu, Z., Ji, M.F., Huang, Q.H., Fang, F., Liu, Q., Jia, W.H., dkk., 2012. Two Epstein-Barr Virus-Related Serologic Antibody Tests in Nasopharyngeal Carcinoma Screening: Results From the Initial Phase of a Cluster Randomized Controlled Trial in Southern China. *American Journal of Epidemiology*, 177(3), 242–250. doi:10.1093/aje/kws404
- Lo, K. W., To, K. F., Huang, D. P., 2004. Focus on nasopharyngeal carcinoma. *Cancer Cell*, 5(5), 423–428. doi:10.1016/s1535-6108(04)00119-9
- Long, M., Fu, Z., Li, P., Nie, Z., 2017. Cigarette smoking and the risk of nasopharyngeal carcinoma: a meta-analysis of epidemiological studies. *BMJ open*, 7(10), e016582. doi:10.1136/bmjopen-2017-016582
- Low, W.K., Leong, J.L., Goh, Y.H., Fong, K.W., 2000. Diagnostic Value of Epstein-Barr Viral Serology in Nasopharyngeal Carcinoma. *Otolaryngology-Head and Neck Surgery*, 123(4), 505–507. doi:10.1067/mhn.2000.108201
- Mahdavifar, N., Ghoncheh, M., Mohammadian-Hafshejani, A., Khosravi, B., Salehiniya, H., 2016. Epidemiology and Inequality in the Incidence and Mortality of Nasopharynx Cancer in Asia. *Osong public health and research perspectives*, 7(6), 360–372. doi:10.1016/j.phrp.2016.11.002
- Mahmood, T., & Yang, P. C., 2012. Western blot: technique, theory, and trouble shooting. *North American journal of medical sciences*, 4(9), 429–434. doi:10.4103/1947-2714.100998
- Marshall, N. A., Vickers, M. A., Barker, R. N., 2003. Regulatory T Cells Secreting IL-10 Dominate the Immune Response to EBV Latent Membrane Protein 1. *The Journal of Immunology*, 170(12), 6183–6189. doi:10.4049/jimmunol.170.12.6183

- Mathew, A., Cheng, H.-M., Sam, C.K., Joab, I., Prasad, U., Cochet, C., 1994. A high incidence of serum IgG antibodies to the Epstein-Barr virus replication activator protein in nasopharyngeal carcinoma. *Cancer Immunology Immunotherapy*, 38(1), 68–70. doi:10.1007/bf01517172
- Meij, P., Vervoort, M. B., Aarbiou, J., van P. Dissel, A., Brink, E., Bloemena, C., J. Meijer., Middeldorp, J. M., 1999. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases. *J. Infect. Dis*, 179, 1108-1115
- Montgomery, K., 2014. Dorothy H Crawford, Alan Rickinson and Ingólfur Johannessen, *Cancer Virus: The Story of Epstein-Barr Virus*. *Scottish Medical Journal*, 59(3), 161–161. doi:10.1177/0036933014541907
- Murray, C. K., & Bennett, J. W., 2009. *Rapid Diagnosis of Malaria. Interdisciplinary Perspectives on Infectious Diseases*, 2009, 1–7. doi:10.1155/2009/415953
- Nam, J. M., McLaughlin, J. K., Blot, W. J., 1992. Cigarette Smoking, Alcohol, and Nasopharyngeal Carcinoma: A Case-Control Study Among U.S. Whites. *JNCI Journal of the National Cancer Institute*, 84(8), 619–622. doi:10.1093/jnci/84.8.619
- Netter, F. H., Hansen, J. T., Lambert, D. R., 2005. *Netter's clinical anatomy*. Carlstadt, N.J: Icon Learning Systems
- Ng, S., Chan, S., Yen, T., dkk., 2009. Pretreatment evaluation of distant-site status in patients with nasopharyngeal carcinoma: accuracy of whole-body MRI at 3-Tesla and FDG-PET-CT. *Eur Radiol*, 19, 2965–2976
- Nielsen, N. H., Mikkelsen, F., Hansen, J. P. H., 2009. Nasopharyngeal cancer in Greenland. *Acta Pathologica Microbiologica Scandinavica Section A Pathology*, 85A(6), 850–858. doi:10.1111/j.1699-0463.1977.tb03900.x
- O'Reilly, R.J., Small, T. N., Papadopoulos, K., Lucas, J., Lacerda, Koulova, L., 1997. Biology and adoptive cell therapy of Epstein-Barr virus associated lymphoproliferative disorders in recipients of marrow allografts. *Immunol Rev*, 157, 195-216
- Omiya, R., Buteau, C., Kobayashi, H., Paya, C. V., Celis, E., 2002. Inhibition of EBV-Induced Lymphoproliferation by CD4+ T Cells Specific for an MHC Class II Promiscuous Epitope. *The Journal of Immunology*, 169(4), 2172–2179. doi:10.4049/jimmunol.169.4.2172

- Papesch, M., & Watkins, R., 2001. Epstein-Barr virus infectious mononucleosis. *Clinical Otolaryngology and Allied Sciences*, 26(1), 3–8. doi:10.1046/j.1365-2273.2001.00431.x
- Pappworth, I.Y., Wang, E.C., Rowe, M., 2007. The switch from latent to productive infection in Epstein-barr virus infected B cels is associated with sensitization to NK cell killing. *J Virol*, 81, 474-82
- Paramita, D. K., 2010. Diagnosis and Protective Aspects of Humoral Immune Response to Epstein-Barr Virus Encoded Protein in Nasopharyngeal Carcinoma.
- Paramita, D. K., Fachiroh, J., Haryana, S. M., and Middeldorp, J. M., 2009. Two-Step Epstein-Barr Virus Immunoglobulin A Enzyme-Linked Immunosorbent Assay System for Serological Screening and Confirmation of Nasopharyngeal Carcinoma. *Clinical and Vaccine Immunology*, 16(5), 706–711. <https://doi.org/10.1128/CVI.00425-08>
- Paramita, D. K., Fachiroh, J., Haryana, S. M., & Middeldorp, J. M., 2008. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma. *Journal of Clinical Virology*, 42(4), 343–352. doi:10.1016/j.jcv.2008.03.006
- Parkin D. M., Whelan S. L., Ferlay J., Teppo L., Thomas D. B., 2002. Cancer incidence in five continents, vol. VIII. IARC scientific publications No. 155. Lyon: IARC
- Pathmanathan, R., Prasad, U., Chandrika, G., Sadler, R., Flynn, K., Raab-Traub, N., 1995. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. *The American journal of pathology*, 146(6), 1355–1367.
- Perhimpunan Dokter Spesialis Telinga Hidung Tenggorok Bedah Kepala Leher Indonesia (PERHATI-KL) & Perhimpunan, 2017. Panduan Praktik Klinis PP PERHATI-KL DI BIDANG TELINGA HIDUNG TENGGOROK-KEPALA LEHER Volume 2.
- Petersson, F., 2015. Nasopharyngeal carcinoma: A review. *Seminars in Diagnostic Pathology*, 32(1), 54–73. doi:10.1053/j.sem dp.2015.02.021
- Rai, G.P., Venkateswaran, K. S., 1992. Limitations and Practical Problems in Enzym-Linked Immunosorbent Assays, *Defence Science Journal*, 2, 71-84
- Ravishankar, B., Rajjesh, R., Venkatanagaraju, E., Divakar, G., Shrees hail, T., Reddy, Y.N., 2015. Overview on development and applications of

imunochromatography. *World Journal of Pharmacy and Pharmaceutical Science*, 4(12), 344-349

Rickinson, A.B., & Moss, D. J., 2006. Epstein-Barr Virus. In D. Knipe and P.Howley (Ed.), *Fields Virology*, 5th ed. Lippincott Williams & Wilkins, Philadelphia

Rickinson, A.B., Callan, M.F., Annels, N.E., 2000. T-Cell memory: lssons from Epstein-Barr virus infection in man. *Philos trans R Soc Lond B BuilSci*, 355, 391-400

Robert, 2009, Kemampuan Alat Deteksi Cepat IgG-EBV dibanding ELISA IgG dan IgA-EBV untuk Mendeteksi Kanker Nasofaring [skripsi], Fakultas Kedokteran Kesehatan Masyarakat dan Keperawatan, Yogyakarta: Universitas Gadjah Mada,

Sajid, M., Kawde, A.N., Daud, M., 2015. Designs, formats and applications of lateral flow assay: A literature review. *Journal of Saudi Chemical Society*, 19(6), 689–705. doi:10.1016/j.jscs.2014.09.001

Scotet, E., David-Ameline, J., Peyrat, M. A., Moreau-Aubry, A., Pinczon, D., Lim, A., dkk., 1996. T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. *The Journal of experimental medicine*, 184(5), 1791–1800. doi:10.1084/jem.184.5.1791

Sham, J. S. T., Poon, Y. F., Wei, W. I., & Choy, D., 1990. Nasopharyngeal carcinoma in young patients. *Cancer*, 65(11), 2606–2610. doi:10.1002/1097-0142(19900601)65:11<2606::aid-cnrc2820651135>3.0.co;2-u

Shanmugaratnam K., Tye C. Y., Goh E. H., Chia K. B., 1978 Etiological factors in nasopharyngeal carcinoma: a hospital-based, retrospective, case-control, questionnaire study. *IARC Sci Publ*, 20,199–212

Smatti, M. K., Al-Sadeq, D. W., Ali, N. H., Pintus, G., Abou-Saleh, H., Nasrallah, G. K., 2018. Epstein-Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update. *Frontiers in oncology*, 8, 211. doi:10.3389/fonc.2018.00211

Soerjomataram, I., Lortet-Tieulent, J., Parkin, D. M., Ferlay, J., Mathers, C., Forman, D., & Bray, F., 2012. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. *The Lancet*, 380(9856), 1840–1850. doi:10.1016/s0140-6736(12)60919-2

Stanfield, B. A., & Luftig, M. A., 2017. Recent advances in understanding Epstein-Barr virus. *F1000Research*, 6, 386. doi:10.12688/f1000research.10591.1

- Steven, N. M., Annels, N. E., Kumar, A., Leese, A. M., Kurilla, M. G., Rickinson, A. B., 1997. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. *The Journal of experimental medicine*, 185(9), 1605–1617. doi:10.1084/jem.185.9.1605
- Stolzenberg, M. C., Debouze, S., Ng, M., dkk., 1996. Purified recombinant EBV desoxyribonuclease in serological diagnosis of nasopharyngeal carcinoma. *International Journal of Cancer*, 66(3), 337–341. doi:10.1002/(sici)1097-0215(19960503)66:3<337::aid-ijc12>3.0.co;2-8
- Tabuchi, K., Nakayama, M., Nishimura, B., Hayashi, K., Hara, A., 2011. Early detection of nasopharyngeal carcinoma. *International journal of otolaryngology*, 2011, 638058. doi:10.1155/2011/638058
- Tang, J. W., Rohwäder, E., Chu, I. M. T., dkk., 2007. Evaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma. *Journal of Clinical Virology*, 40(4), 284–288. doi:10.1016/j.jcv.2007.09.006
- Tang, L L., Chen, Y.P., Mao, Y.P., Wang, Z.X., Guo, R., Chen, L., Ma, J., 2017. Validation of the 8th Edition of the UICC/AJCC Staging System for Nasopharyngeal Carcinoma From Endemic Areas in the Intensity-Modulated Radiotherapy Era. *Journal of the National Comprehensive Cancer Network*, 15(7), 913–919. doi:10.6004/jnccn.2017.0121
- Tedeschi, R., Foong, Y. T., Cheng, H. M., dePaoli, P., Lehtinen, T., Elfborg, T., & Dillner, J., 1995. The disease associations of the antibody response against the Epstein--Barr virus transactivator protein ZEBRA can be separated into different epitopes. *Journal of General Virology*, 76(6), 1393–1400. doi:10.1099/0022-1317-76-6-1393
- Teo, P. M. L., Tsao, S. Y., Hoe, J. H. C., Yu, P., 1991. A proposed modification of the Ho stage-classification for nasopharyngeal carcinoma. *Radiotherapy and Oncology*, 21(1), 11–23. doi:10.1016/0167-8140(91)90336-f
- Trottier H., Buteau C., Robitaille N., dkk., 2012. Transfusion-related Epstein-Barr virus infection among stem cell transplant recipients: a retrospective cohort study in children. *Transfusion*, 52(12):2653–63. doi: 10.1111/j.1537-2995.2012.03611.x
- Tsao, S. W., Tsang, C. M., & Lo, K. W., 2017. Epstein–Barr virus infection and nasopharyngeal carcinoma. *Philosophical Transactions of the Royal Society B: Biological Sciences*, 372(1732), 20160270. doi:10.1098/rstb.2016.0270
- Tsao, S. W., Yip, Y. L., Tsang, C. M., Pang, P. S., Lau, V. M. Y., Zhang, G., Lo, K. W., 2014. Etiological factors of nasopharyngeal carcinoma. *Oral Oncology*, 50(5), 330–338. doi:10.1016/j.oraloncology.2014.02.006
- Tuan, J. K. L., Ha, T. C., Ong, W. S., Siow, T. R., Tham, I. W. K., Yap, S. P., dkk., 2012. Late toxicities after conventional radiation therapy alone for nasopharyngeal carcinoma. *Radiotherapy and Oncology*, 104(3), 305–311. doi:10.1016/j.radonc.2011.12.028

- Vaughan, T.L., Shapiro, J.A., Burt, R.D., Swanson, G.M., Berwick, M., dkk. 1996. Nasopharyngeal cancer in a low-risk population: defining risk factors by histological type. *Cancer Epidemiol Biomarkers Prev* August 1, 5(8) 587-593
- Veldeman, L., Madani, I., Hulstaert, F., De Meerleer, G., Mareel, M., & De Neve, W., 2008. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. *The Lancet Oncology*, 9(4), 367–375. doi:10.1016/s1470-2045(08)70098-6
- Vokes, E. E., Liebowitz, D. N., Weichselbaum, R. R., 1997. Nasopharyngeal carcinoma. *The Lancet*, 350(9084), 1087–1091. doi:10.1016/s0140-6736(97)07269-3
- Wee, J.T., Ha, T.C., Loong, S.L., Qian, C., 2010. Is nasopharyngeal cancer really a "Cantonese cancer"? *Chinese journal of cancer*, 29 5, 517-26 .
- Wei, W. I., & Kwong, D. L., 2010. Current management strategy of nasopharyngeal carcinoma. *Clinical and experimental otorhinolaryngology*, 3(1), 1–12. doi:10.3342/ceo.2010.3.1.1
- Wei, W. I., Chan, J. Y. W., Ng, R. W. M., Ho, W. K., 2010. Surgical salvage of persistent or recurrent nasopharyngeal carcinoma with maxillary swing approach - Critical appraisal after 2 decades. *Head & Neck*, 33(7), 969–975. doi:10.1002/hed.21558
- WHO, 2014. Nasopharyngeal Carcinoma Union for International Cancer Control 2014 Review of Cancer Medicine on the HO List of Essential Medicine.
- Wildeman, M. A., Fles, R., Adham, M., dkk., 2012. Short-term effect of different teaching methods on nasopharyngeal carcinoma for general practitioners in Jakarta, Indonesia. *PloS one*, 7(3), e32756. doi:10.1371/journal.pone.0032756
- Williams, H., McAulay, H., Macsween, K. F., Gllacher, N.J., Higgins, C.D., Harrison, N., Swerdlow, A.J., Crawford, D. H., 2005. The immune response to primary EBV infection: a role for natural killer cells. *Br J Haematol*, 129, 266-74
- Wu, C. C., Liu, M. T., Chang, Y. T., dkk., 2010. Epstein-Barr virus DNase (BGLF5) induces genomic instability in human epithelial cells. *Nucleic acids research*, 38(6), 1932–1949. doi:10.1093/nar/gkp1169
- Wu, S. Y., Wu, Y. H., Yang, M. W., dkk., 2014. Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up. *BMC cancer*, 14, 787. doi:10.1186/1471-2407-14-787
- Xie, S. H., Yu, I. T. S., Tse, L. A., Mang, O. W., Yue, L., 2013. Sex difference in the incidence of nasopharyngeal carcinoma in Hong Kong 1983–2008: Suggestion of a potential protective role of oestrogen. *European Journal of Cancer*, 49(1), 150–155. doi:10.1016/j.ejca.2012.07.004

- Xu FH, Xiong D, Xu YF, dkk., 2004. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. *J Natl Cancer Inst*, 104, 1396–410.
- Yip, T. T. C., Ngan, R. K. C., Lau, W. H., Poon, Y. F., Joab, I., Cochet, C., Cheng, K. P., 1994. A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. *Cancer*, 74(9), 2414–2424. doi:10.1002/1097-0142(19941101)74:9<2414::aid-cncr2820740905>3.0.co;2-8
- Yu, M. C., Yuan, J., 2002. Epidemiology of nasopharyngeal carcinoma. *Seminars in Cancer Biology*, 12(6), 421–429. doi:10.1016/s1044579x02000858
- Zhang, L., Chen, Q. Y., Liu, H., Tang, L. Q., Mai, H. Q., (2013). Emerging treatment options for nasopharyngeal carcinoma. *Drug design, development and therapy*, 7, 37–52. doi:10.2147/DDDT.S30753
- Zhuo, X., Cai, L., Xiang, Z., Li, Q., Zhang, X., 2009. GSTM1 and GSTT1 polymorphisms and nasopharyngeal cancer risk: an evidence-based meta-analysis. *Journal of experimental & clinical cancer research: CR*, 28(1), 46. doi:10.1186/1756-9966-28-46
- Zong, Y. S., Zhang, R. F., He, S. Y., dkk., 1983. Histopathologic types and incidence of malignant nasopharyngeal tumors in Zhongshan County [J] *Chin Med J (Engl)*, 96(7), 511–516.